January 15, 2008 – On March 7 and 8, Yale School of Medicine and Nevada Cancer Institute (NVCI) will hold the Second Annual John R. Murren Memorial Symposium: “Advances in Thoracic Oncology” at The Red Rock Conference Center in Las Vegas.

The Yale School of Medicine designates this educational activity for a maximum of 8.5 AMA PRA Category 1 Credits.

John Murren M.D. was among the founders of both The Yale Cancer Center Thoracic Oncology Program and Nevada Cancer Institute. In honor of his efforts, the Course Directors, Drs. Lynn Tanoue, Nicholas Vogelzang, Giuseppe Pizzorno, and Daniel M. Goodenberger have gathered 10 “of the most formidable minds in cancer research in the area of thoracic oncology” to provide evidence-based education to multidisciplinary clinicians involved in the screening, diagnosis and treatment of patients with lung cancer and abnormal scans of the chest.

Participants who attend will be able to:
- Report on the current state of lung cancer care
- Review innovations in minimally invasive thoracic surgery and bronchoscopy
- Apply new advances in imaging for small pulmonary nodules
- Identify novel approaches to radiotherapy for lung cancer
- Assess updates in mesothelioma
- Engage in pathologic evaluation of bronchoalveolar carcinoma
- Discuss molecular pharmacology in lung cancer
- Understand and apply novel and targeted therapies for lung cancer
- Integrate evidence-based guidelines for lung cancer staging and
- Analyze current strategies of prevention and therapy

For more information: www.cme.yale.edu


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now